Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Jade Biosciences, Inc.NASDAQ: JBIO
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$214.76M, compared with -$235.57M a year earlier.
Context
- Retained earnings amounted to 67.2% of total assets at the end of Q1 FY2026, down 236.6 pp from a year earlier.
- Retained earnings grew in size in 2 of the last 3 fiscal years.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +8.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (174.39M) USD
- Year-over-year change
- +25.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (174.39M) | +25.2% |
| FY2024 | 2024-12-31 | (233.05M) | -42.6% |
| FY2023 | 2023-12-31 | (163.42M) | -85.9% |
| FY2022 | 2022-12-31 | (87.9M) | -141.5% |
| FY2021 | 2021-12-31 | (36.39M) | — |
Retained Earnings vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's Mar 2026 retained earnings of -$214.76M is the 4th highest of the 9 companies compared; the peer median is -$452.39M.
- Its year-over-year change of +8.8% is the highest of 8, against a peer median of -43.8%.
- Retained earnings amounts to 67.2% of total assets for JBIO, versus a peer median of 156.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | -$113.06M | -33.4% | — | 118.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | -$191.84M | -43.8% | — | 73.4% |
| Mar 2026 | -$214.76M | +8.8% | — | 67.2% | |
| Mar 2026 | -$440.23M | -21.6% | — | 300.2% | |
| Mar 2026 | -$464.56M | -50.8% | — | 180.7% | |
| Mar 2026 | -$532.62M | -93.3% | — | 133.0% | |
| Mar 2026 | -$987.61M | -7.6% | — | 497.0% | |
| Jun 2026 | -$991.37M | -68.2% | — | 186.0% | |
| Peer median (excluding JBIO) | -$452.39M | -43.8% | — | 156.9% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.2M | 22.4M | 23.49M | 33.75M | 88.44M |
| Short-term Investments | 113.18M | 106.82M | 98.95M | 44.87M | 247.72M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 240K | 295K | 250K | 845K | 0 |
| Total Current Assets | 174.33M | 131.5M | 124.23M | 80.12M | 336.16M |
| Property, Plant & Equipment (Net) | 728K | 1.25M | 902K | 215K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 302K | 2.56M | 2.28M | 0 | 13.62M |
| Total Non-current Assets | 1.03M | 3.8M | 3.19M | 215K | 13.62M |
| Total Assets | 175.36M | 135.3M | 127.42M | 80.33M | 349.78M |
| Account Payables | 1.21M | 2.58M | 2.4M | 224K | 2.15M |
| Short-term Debt | 192K | 385K | 420K | 417K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 360K | 3.13M | 10.45M | 319K | 3.32M |
| Total Current Liabilities | 2.55M | 7.78M | 17.64M | 3.83M | 16.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13K | 71K | 70K | 70K | 0 |
| Total Non-current Liabilities | 395K | 776K | 325K | 70K | 724K |
| Total Liabilities | 2.95M | 8.56M | 17.96M | 3.9M | 17.26M |
| Common Stock | 2K | 2K | 3K | 3K | 5K |
| Retained Earnings | (36.39M) | (87.9M) | (163.42M) | (233.05M) | (174.39M) |
| Accumulated OCI | (59K) | (466K) | 237K | 105K | 129K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 172.42M | 126.74M | 109.46M | 76.43M | 332.52M |
| Total Debt | 574K | 1.09M | 675K | 417K | 724K |
| Net Debt | (53.62M) | (21.31M) | (22.82M) | (33.33M) | (87.71M) |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.